
Sign up to save your podcasts
Or


In this episode of The Psychedelic Podcast, Paul F. Austin is joined by renowned neuroscientist Dr. Robin Carhart-Harris and microdosing policy advocate John Downs for a replay of a live event originally held on June 10th, Microdosing vs. SSRIs: What's Happening in the Brain and Why It Matters. Find full show notes and links here: https://thethirdwave.co/podcast/episode-312b/?ref=278 Together, they explore the scientific distinctions between SSRIs and psychedelics, focusing on neuroimaging, brain entropy, emotional processing, and the REBUS model. Dr. Carhart-Harris shares key insights from landmark studies on psilocybin therapy and discusses the evidence (and limitations) around microdosing. John Downs closes the conversation with an update on the Microdosing Collective's efforts to shift policy and expand access.
Robin Carhart-Harris, PhD is a neuropharmacologist, psychologist, and Ralph Metzner Distinguished Professor in Neurology and Psychiatry at the University of California, San Francisco. He leads the Psychedelics Division at UCSF's Neuroscape and formerly founded and led the Centre for Psychedelic Research at Imperial College London.
John Downs is Executive Director of the Microdosing Collective, advocating for responsible policy reform and legal access to microdosing. With 25 years' experience in sales, business development, and emerging markets, John helps individuals optimize mindset, performance, and purpose. Episode Highlights:
Episode Links:
Episode Sponsors:
By Third Wave4.7
303303 ratings
In this episode of The Psychedelic Podcast, Paul F. Austin is joined by renowned neuroscientist Dr. Robin Carhart-Harris and microdosing policy advocate John Downs for a replay of a live event originally held on June 10th, Microdosing vs. SSRIs: What's Happening in the Brain and Why It Matters. Find full show notes and links here: https://thethirdwave.co/podcast/episode-312b/?ref=278 Together, they explore the scientific distinctions between SSRIs and psychedelics, focusing on neuroimaging, brain entropy, emotional processing, and the REBUS model. Dr. Carhart-Harris shares key insights from landmark studies on psilocybin therapy and discusses the evidence (and limitations) around microdosing. John Downs closes the conversation with an update on the Microdosing Collective's efforts to shift policy and expand access.
Robin Carhart-Harris, PhD is a neuropharmacologist, psychologist, and Ralph Metzner Distinguished Professor in Neurology and Psychiatry at the University of California, San Francisco. He leads the Psychedelics Division at UCSF's Neuroscape and formerly founded and led the Centre for Psychedelic Research at Imperial College London.
John Downs is Executive Director of the Microdosing Collective, advocating for responsible policy reform and legal access to microdosing. With 25 years' experience in sales, business development, and emerging markets, John helps individuals optimize mindset, performance, and purpose. Episode Highlights:
Episode Links:
Episode Sponsors:

10,534 Listeners

1,850 Listeners

2,634 Listeners

1,478 Listeners

1,287 Listeners

569 Listeners

505 Listeners

1,011 Listeners

1,644 Listeners

1,046 Listeners

470 Listeners

611 Listeners

114 Listeners

149 Listeners

8,610 Listeners